SCHEMBL4292263

SCHEMBL4292263

Cn1ncc(Br)c(Br)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.50
ALDH1A1 P00352 5/20 0.50
MAPT P10636 5/20 0.50
RAB9A P51151 5/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
HTT P42858 3/20 0.50
NPSR1 Q6W5P4 3/20 0.50
RXFP1 Q9HBX9 2/20 0.50
MITF O75030 2/20 0.50
XBP1 P17861 2/20 0.50
S1PR4 O95977 1/20 0.50
S1PR1 P21453 1/20 0.50
LMNA P02545 2/20 0.48
PAX8 Q06710 2/20 0.48
MTOR P42345 1/20 0.45
GAA P10253 1/20 0.45
KAT2B Q92831 6/20 0.42
BRD9 Q9H8M2 5/20 0.42
BPTF Q12830 2/20 0.42
TRPC5 Q9UL62 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8545709 0.80 BRD9 (0.42) NPC1ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL8281635 0.78 MTOR (0.43) NPC1ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL17912381 0.78 KAT2B (0.47) ALDH1A1MAPTRAB9ANPSR1MTOR
SCHEMBL17912364 0.78 KAT2B (0.56) ALDH1A1MAPTRAB9ANPSR1GAA
SCHEMBL13620238 0.77 RAB9A (0.55) NPC1ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL14844575 0.77 NPBWR1 (0.43) NPC1ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL8549796 0.75 MTOR (0.38) NPC1ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL4498149 0.75 RAB9A (0.55) NPC1ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL8544525 0.74 SMN1; SMN2 (0.40) NPC1ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL9233774 0.72 SMN1; SMN2 (0.50) NPC1ALDH1A1MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025245484-A1 FOXN1 ACTIVATORS THYMOFOX INC. (US) 2025-11-27 WO disclosed
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 EP disclosed
WO-2025076219-A1 METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE Design Therapeutics, Inc. (US) 2025-04-10 WO disclosed
WO-2025076236-A1 METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE Design Therapeutics, Inc. (US) 2025-04-10 WO disclosed
WO-2025076181-A1 METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE Design Therapeutics, Inc. (US) 2025-04-10 WO disclosed
WO-2024220843-A1 TECHNOLOGIES TARGETING CELL STATES AURON THERAPEUTICS, INC. (US) 2024-10-24 WO disclosed
WO-2024132895-A1 MICROBIOCIDAL DIHYDROOXADIAZINYL PYRIDAZINONE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2024-06-27 WO disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 WO disclosed
US-20230391730-A1 INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS REGENTS OF THE UNIVERSITY OF MINNESOTA 2023-12-07 US disclosed
WO-2023166067-A1 MICROBIOCIDAL PYRIDAZINONE AMIDE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2023-09-07 WO disclosed
US-5763439-A POTENTIATION ISHIHARA SANGYO KAISHA LTD. (JP) 1998-06-09 US disclosed
US-5723411-A Herbicidal pyridazinones E. I. DU PONT DE NEMOURS AND COMPANY (US) 1998-03-03 US disclosed
EP-0717734-A1 PYRIDAZINONE DERIVATIVES OR THEIR SALTS, PROCESSES FOR THEIR PRODUCTION, AND ANTI-SHOCK AGENTS CONTAINING THEM ISHIHARA SANGYO KAISHA, LTD. (JP) 1996-06-26 EP disclosed
WO-1995007264-A1 PYRIDAZINONE DERIVATIVES OR THEIR SALTS, PROCESSES FOR THEIR PRODUCTION, AND ANTI-SHOCK AGENTS CONTAINING THEM ISHIHARA SANGYO KAISHA LTD. (JP) 1995-03-16 WO disclosed
EP-0372305-B1 PIPERAZINYLALKYL-3(2H)-PYRIDAZINONES, METHOD FOR THEIR PREPARATION AND THEIR USE AS ANTIHYPERTENSIVE AGENTS Hafslund Nycomed Pharma Aktiengesellschaft (AT) 1993-08-04 EP disclosed
US-5034391-A Piperazinylalkyl-3(2H)-pyridazinones and the use thereof as agents lowering blood pressure CL PHARMA AKTIENGESELLSCHAFT (AT) 1991-07-23 US disclosed
EP-0372305-A1 Piperazinylalkyl-3(2H)-pyridazinones, method for their preparation and their use as antihypertensive agents Hafslund Nycomed Pharma Aktiengesellschaft (AT) 1990-06-13 EP disclosed
EP-0135076-B1 PYRIDAZINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES BASF Aktiengesellschaft (DE) 1987-07-29 EP disclosed
US-4663324-A PRETREATMENT BASF AKTIENGESELLSCHAFT (DE) 1987-05-05 US disclosed
EP-0135076-A2 Pyridazinone derivatives, process for their preparation and their use as fungicides BASF Aktiengesellschaft (DE) 1985-03-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391730-A1 INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS BPTF, BRPF3, PHF6 NPC1 2634/4885ALDH1A1 2997/4885MAPT 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.